Biomarkers predict benefit of targeted therapy in metastatic renal-cell cancer
 

In metastatic renal-cell cancer, the level of cytokines and angiogenic factors identify those patients with an aggressive disease course who derive the greatest benefit from treatment with the molecular-targeted therapy pazopanib, a retrospective analysis of clinical trials shows.Licensed from Medwire news with permission from Springer Healthcare Ltd. ©Springer Healthcare Ltd. All rights reserved. Neither of these parties endorse or recommend any commercial products, services, or equipment.



More...